Bringing the Oncology Community Together

Dr. Gomella on the Value of a Multidisciplinary Cancer Center

Leonard G. Gomella, MD
Published Online: Wednesday, February 27, 2013


Leonard Gomella, MD, professor and chair of the Department of Urology, describes the history and effectiveness of the genitourinary cancers multidisciplinary clinic at the Thomas Jefferson University Hospital Kimmel Cancer Center, in Philadelphia.

Gomella, one of the clinic's founders, explains that the multidisciplinary clinic was initially launched in 1996 to address the growing number of treatment options becoming available for men with prostate cancer. Since its founding, the clinic has grown substantially and provides many benefits, including: convenience for the patient, educational value not only for families but for trainees, fellows, and residents, and recruitment to clinical trials.

In general, the multidisciplinary approach is effective because it allows for the collaboration of various specialists and ancillary personnel, such as social workers, nutritional therapists, and clinical trial coordinators in a single visit. Through this collaboration, the doctors are able to give each patient a definitive treatment recommendation in a shorter more efficient timeframe. This system, Gomella believes, is especially helpful in patients with localized prostate cancer, who otherwise might need a series of appointments to learn about a variety of potential treatments, with little evidence to support one therapy over another.

Related Articles
Early Detection of Metastatic Prostate Cancer
In this segment, panelists discuss advanced imaging techniques that can be used to detect metastases earlier for patients with castration-resistant prostate cancer.
Adding ADT to RT Reduces Risk of Progression in Localized Prostate Cancer
Patients with localized prostate cancer at intermediate or high risk for progression experience better outcomes when 6 months of androgen deprivation therapy is added to standard radiotherapy.
Pretreatment Genetic Test Predicts Recurrence in Prostate Cancer
A novel 100-locus DNA signature obtained from pretreatment biopsies accurately classified 75% of patients with untreated prostate cancer as low- or high-risk.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.